HC Wainwright Raises Earnings Estimates for Biomea Fusion

Biomea Fusion, Inc. (NASDAQ:BMEA) – Equities research analysts at HC Wainwright boosted their FY2026 earnings per share (EPS) estimates for Biomea Fusion in a research note issued on Thursday, August 6th. HC Wainwright analyst J. Pantginis now expects that the company will earn ($0.65) per share for the year, up from their previous estimate of ($0.69). The consensus estimate for Biomea Fusion’s current full-year earnings is ($0.75) per share. HC Wainwright also issued estimates for Biomea Fusion’s FY2027 earnings at ($0.66) EPS and FY2028 earnings at ($0.79) EPS.

BMEA has been the subject of several other research reports. Citigroup began coverage on Biomea Fusion in a report on Tuesday, May 5th. They issued an “outperform” rating for the company. Weiss Ratings downgraded shares of Biomea Fusion from a “sell (d-)” rating to a “sell (e+)” rating in a report on Wednesday, July 1st. D. Boral Capital reaffirmed a “buy” rating and set a $12.00 price objective on shares of Biomea Fusion in a report on Tuesday, April 28th. Wall Street Zen lowered shares of Biomea Fusion from a “hold” rating to a “sell” rating in a research report on Saturday, May 30th. Finally, Citizens Jmp started coverage on shares of Biomea Fusion in a research note on Tuesday, May 5th. They issued a “market outperform” rating and a $9.00 target price for the company. Five investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to MarketBeat, Biomea Fusion has a consensus rating of “Moderate Buy” and an average target price of $8.20.

Biomea Fusion Price Performance

Shares of NASDAQ BMEA opened at $1.29 on Monday. Biomea Fusion has a one year low of $0.87 and a one year high of $2.99. The business’s fifty day moving average price is $1.27 and its 200-day moving average price is $1.38. The stock has a market capitalization of $93.50 million, a PE ratio of -4.45 and a beta of -0.28.

Biomea Fusion (NASDAQ:BMEA) last announced its quarterly earnings data on Thursday, August 6th. The company reported ($0.12) earnings per share for the quarter, beating the consensus estimate of ($0.22) by $0.10.

Institutional Trading of Biomea Fusion

Several institutional investors and hedge funds have recently bought and sold shares of the company. Vanguard Group Inc. boosted its holdings in Biomea Fusion by 15.4% in the 3rd quarter. Vanguard Group Inc. now owns 2,170,066 shares of the company’s stock valued at $4,384,000 after purchasing an additional 290,376 shares during the period. Renaissance Technologies LLC grew its position in shares of Biomea Fusion by 174.3% during the 1st quarter. Renaissance Technologies LLC now owns 1,312,798 shares of the company’s stock valued at $2,009,000 after purchasing an additional 834,179 shares in the last quarter. Marshall Wace LLP increased its holdings in shares of Biomea Fusion by 293.7% in the fourth quarter. Marshall Wace LLP now owns 1,160,351 shares of the company’s stock worth $1,439,000 after purchasing an additional 865,618 shares during the period. BlackRock Inc. bought a new position in shares of Biomea Fusion in the second quarter worth $1,052,000. Finally, Fideuram Intesa Sanpaolo Private Banking S.P.A. purchased a new stake in shares of Biomea Fusion in the fourth quarter worth $783,000. 96.72% of the stock is currently owned by hedge funds and other institutional investors.

About Biomea Fusion

Biomea Fusion, Inc (NASDAQ:BMEA) is a clinical‐stage biopharmaceutical company headquartered in Carlsbad, California. The company is dedicated to the discovery and development of small molecule therapies that target epigenetic regulators implicated in cancer. By leveraging a proprietary chemistry and drug discovery platform, Biomea Fusion aims to design precision medicines that modulate gene expression pathways involved in the initiation and progression of hematological malignancies and solid tumors.

The company’s lead clinical asset, BMF-219, is an orally bioavailable inhibitor of the menin–mixed‐lineage leukemia (MLL) protein–protein interaction.